ERAS · Erasca Inc
United States · RS rating 70 · As of 2026-11-03
| Price | 14.64 USD |
|---|---|
| 1-day change | +4.2% |
| RS rating (overall / 1M / 3M / 12M) | 70 / 55 / 30 / 98 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 38 / 38 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +9.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +34.9% |
| Market cap (USD) | $7.0B |